Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study

被引：0
|
作者：
Zhang, G. [1 ]
He, Y. [1 ]
Luo, D. [1 ]
Zhang, X. [1 ]
Gao, B. [1 ]
Jiang, Y. [1 ]
Zhao, J. [1 ]
Guo, L. [1 ]
Xu, Y. [1 ]
机构：
[1] Army Specialty Med Ctr PLA, Dept Breast & Thyroid Surg, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26TiP
引用
收藏
页码：S1414 / S1414
页数：1
相关论文
共 50 条
  • [21] Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
    Lu, Changchang
    Zhu, Yahui
    Kong, Weiwei
    Yang, Ju
    Zhu, Linxi
    Wang, Lei
    Tang, Min
    Chen, Jun
    Li, Qi
    He, Jian
    Li, Aimei
    Qiu, Xin
    Gu, Qing
    Chen, Dongsheng
    Meng, Fanyan
    Liu, Baorui
    Qiu, Yudong
    Du, Juan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Phase II open, single-arm trial: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple-negative breast cancer
    Alvarado Miranda, A.
    Lara Medina, F. U.
    Arce, C.
    Castaneda-Soto, N.
    Cano Blanco, C.
    Aguilar Ponce, J. L.
    Bargallo Rocha, E.
    Perez-Sanchez, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
    Parton, Marina
    Bardia, Aditya
    Kummel, Sherko
    Estevez, Laura G.
    Huang, Chiun-Sheng
    Castan, Javier Cortes
    Borrego, Manuel Ruiz
    Telli, Melinda L.
    Lluch, Ana
    Lopez, Rafael
    Beck, J. Thaddeus
    Ismail-Khan, Roohi
    Chen, Shin-Cheh
    Hurvitz, Sara A.
    Mayer, Ingrid A.
    Atienza, Rolando S.
    Cameron, Scott
    Krygowski, Mizue
    Kim, Sung-Bae
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] The overall survival data of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase II trial
    Wang, Z.
    Chen, L.
    Fan, L.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [25] The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study
    Chen, Xi
    Wei, Xinyu
    Yao, Peizhuo
    Liu, Yanbin
    Guan, Haitao
    Kang, Huafeng
    Liu, Di
    Diao, Yan
    Ma, Xiaobin
    Min, Weili
    Shan, Changyou
    Zhao, Yang
    Zhao, Fang
    Chen, Yuanyuan
    Xiao, Dong
    She, Qing
    Liu, Youhuai
    Zhang, Yinbin
    Zhang, Shuqun
    CLINICAL BREAST CANCER, 2024, 24 (04) : 195 - 202
  • [26] Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial.
    Huang, Weiwei
    Chen, Qi
    Shen, Yangkun
    Wang, Chenxi
    Huang, Zhijian
    Liu, Jian
    Wang, Lili
    Wu, Fan
    Chen, Xinhua
    Li, Nani
    Hong, Yi
    Chen, Mulan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
    Julia Foldi
    Andrea Silber
    Emily Reisenbichler
    Kamaljeet Singh
    Neal Fischbach
    Justin Persico
    Kerin Adelson
    Anamika Katoch
    Nina Horowitz
    Donald Lannin
    Anees Chagpar
    Tristen Park
    Michal Marczyk
    Courtney Frederick
    Trisha Burrello
    Eiman Ibrahim
    Tao Qing
    Yalai Bai
    Kim Blenman
    David L. Rimm
    Lajos Pusztai
    npj Breast Cancer, 7
  • [28] Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
    Foldi, Julia
    Silber, Andrea
    Reisenbichler, Emily
    Singh, Kamaljeet
    Fischbach, Neal
    Persico, Justin
    Adelson, Kerin
    Katoch, Anamika
    Horowitz, Nina
    Lannin, Donald
    Chagpar, Anees
    Park, Tristen
    Marczyk, Michal
    Frederick, Courtney
    Burrello, Trisha
    Ibrahim, Eiman
    Qing, Tao
    Bai, Yalai
    Blenman, Kim
    Rimm, David L.
    Pusztai, Lajos
    NPJ BREAST CANCER, 2021, 7 (01)
  • [29] A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer
    Werner, Theresa L.
    Ray, Abhijit
    Lamb, John G.
    VanBrocklin, Matthew
    Hueftle, Kristin
    Cohen, Adam L.
    Beck, Anna C.
    Buys, Saundra S.
    Dyess, Donna L.
    Butler, Thomas W.
    Dumlao, Theresa L.
    Neumayer, Leigh
    Khong, Hung T.
    CLINICAL BREAST CANCER, 2017, 17 (07) : 503 - 509
  • [30] Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
    Zhang, T.
    Yu, D.
    Wang, J.
    Liu, J.
    Ma, H.
    Lin, Z.
    Jin, M.
    Zhang, J.
    Zhao, L.
    Liu, H.
    Hu, J.
    Zhang, Q.
    ANNALS OF ONCOLOGY, 2021, 32 : S1057 - S1058
12345